February 17, 2021 17:00 ET | Source: ChemoCentryx, Inc. — Treatment with avacopan in the absence of daily oral prednisone led to remission at week 26 and superiority in sustaining remission at 52 weeks compared to the prednisone group — — Avacopan’s effects on kidney function, patient Quality of Life,…...
Pitt Scientists Identify Genetic Risks of Rare Inflammatory Disease
PITTSBURGH, Dec. 11, 2020 – In a paper published today in the American Journal of Human Genetics, a group of international collaborators led by researchers from the University of Pittsburgh School of Medicine identified new genetic associations that can predict individual susceptibility to a rare inflammatory disease called Takayasu arteritis.…...
Scientists use Clues in the Human Genome to Discover new Inflammatory Syndrome
“Our team of researchers at the NIH discovered a new form of vasculitis and called it VEXAS. VEXAS is caused by genetic mutations in a portion of a patient’s blood cells. Before we knew about VEXAS, these patients were diagnosed with other forms of vasculitis, such as relapsing polychondritis, polyarteritis…...
Recruiting: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA)
This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroid (CS) taper regimen compared to placebo in combination with a 52-week CS taper regimen, as measured by the proportion of participants in sustained remission at Week…...
FDA approves Nucala as the first and only biologic treatment for Hypereosinophilic Syndrome (HES)
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases Issued: 25 September 2020, London UK GlaxoSmithKline plc (GSK) today announced the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for the treatment of adult and pediatric patients aged 12…...
